A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Phase 4

Active, not recruiting

• Conditions: Diabetic Macular Edema
• Interventions: Drug: Iluvien 0.19 MG Drug Implant; Drug: Aflibercept

• Registration Number: NCT04469595
• Lead Sponsor: Alimera Sciences

Brief Summary

This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-09
• Study First Submitted QC: 2020-07-13
• Study First Posted: 2020-07-14
• Study Start: 2020-08-31
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-30
• Last Update Posted: 2024-07-31
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1. Male or female subjects ≥18 years of age at the time of consent.
2. Must have CI-DME confirmed by Spectral Domain Ocular Coherence Tomography (SD-OCT) and Center Subfield Thickness (CST) of: ≥350 µm in the study eye.
3. Best Corrected Visual Acuity (BCVA) of ≤80 ETDRS Letters and ≥35 ETDRS letters in the study eye at Screening Visit.

Major

Read More

Exclusion Criteria

1. Patients with Proliferative Diabetic Retinopathy (PDR); high risk proliferative diabetic retinopathy in the study eye and related complications.

2. History or current diagnosis of glaucoma or ocular hypertension (OHT) or a cup to disc ratio >0.8; History of uncontrolled intraocular pressure (defined as IOP ≥25 mmHg with maximum topical and systemic medical hypotensive treatment) or previous filtration surgery in the study eye at Screening Visit.

3. Other conditions that can cause macular edema.

4. Patients who received prior LASER photocoagulation therapy including macular grid or pan retina photocoagulation (PRP) at any time in the study eye. Prior focal LASER photocoagulation therapy outside the macula is allowed.

5. Patients who received the following therapies in the study eye:

   1. Intravitreal or periocular steroids;
   2. Intravitreal injection of aflibercept, brolucizumab, or conbercept ≤12 months prior to Screening Visit

6. Patients who received >1 intravitreal injection of ranibizumab or bevacizumab in the last 12 months; or have received ranibizumab or bevacizumab ≤6 weeks prior to Screening Visit

7. Patients who have lens opacities due to cataract or other etiologies that would make it difficult to examine the fundus or that affect the patients Activities of Daily Living (ADL).

8. Steroid Challenge Exclusion Criterion- At the Baseline Visit, patients who are determined to have an IOP ≥25 mmHg or an increase ≥8 mmHg from Screening will be excluded from the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ILUVIEN Arm	Iluvien 0.19 MG Drug Implant	Intravitreal ILUVIEN
ILUVIEN Arm	Aflibercept	Intravitreal ILUVIEN
Aflibercept Arm	Aflibercept	Intravitreal aflibercept

Primary Outcome Measures

Name	Time	Method
The mean total number of supplemental aflibercept injections needed during the study	Baseline to 18 months	The mean total number of supplemental aflibercept injections needed during

Secondary Outcome Measures

Name	Time	Method
Mean change from baseline in Center Subfield Thickness (CST)	Baseline to 18 months	Mean change from baseline in Center Subfield Thickness (CST)
Proportion of subjects with 15, 10 and 5 letter (ETDRS) gains from baseline	At 18 months	Proportion of subjects with 15, 10 and 5 letter (ETDRS) gains from baseline
Area under the curve (AUC) of Center Subfield Thickness (CST)	Baseline to 18 months	Area under the curve (AUC) of Center Subfield Thickness (CST)
Mean change from baseline in the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score and subscale scores	At 18 months	The NEI VFQ-25 is a questionnaire that allows the individual to report on their level of visual function. Scores range from 0-100, with a score of 0 being the worst outcome and 100 being the best outcome.
Safety Outcome Endpoints: The incidence and severity of treatment-related adverse events	Baseline to 18 months	The incidence and severity of treatment-related adverse events
Area under the curve (AUC) of Best Corrected Visual Acuity (BCVA)	Baseline to 18 months	Area under the curve (AUC) of Best Corrected Visual Acuity (BCVA)

Trial Locations

Locations (1)

Investigative Site; 🇺🇸 Warrenton, Virginia, United States